Soros Fund Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Soros Fund Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-267	Closed	-$2.27M	–	293
2015 Q1	$2.27M	Buy	+267	New	+$2.33M	0.02%	187

Other funds holding EIGR

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Soros Fund Management's EIGR Position: Q2 2015 in Review

Soros Fund Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2015, closing a stake of 267 shares — an estimated $2.27M sold.

Soros Fund Management first reported a position in EIGR in Q1 2015 and held it in 1 quarter. The position peaked at $2.27M in Q1 2015. 44 funds tracked by Wall St. Rank hold EIGR as of Q2 2015.

Soros Fund Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
Soros Fund Management sold 267 Eiger BioPharmaceuticals, Inc. shares in Q2 2015, an estimated $2.27M.
Soros Fund Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2015 and held it in 1 quarter.
Soros Fund Management's Eiger BioPharmaceuticals, Inc. position peaked at $2.27M in Q1 2015.
44 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2015.

Based on Soros Fund Management's 13F filing for Q2 2015, filed 14 Aug 2015.